---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-050163"
form_type: "8-K"
ticker: "BLFS"
cik: "0000834365"
company_name: "BIOLIFE SOLUTIONS INC"
filed_at: "2025-11-06T23:59:59+00:00"
generated_at: "2026-05-17T00:06:26.269880+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# BioLife Q3 total rev $28.1M (+31% YoY); net income $0.6M; raises cell processing guidance to $93-94M

## Summary
- Total Q3 revenue $28.1M (up 31% YoY); Cell Processing revenue $25.4M (up 33% YoY).
- GAAP net income $0.6M vs loss $0.5M in Q3 2024; adjusted EBITDA $7.8M (28% of revenue).
- Full-year Cell Processing revenue guidance raised to $93-94M (from $91-93M); total rev $95-96M excl. evo.
- Completed sale of evo cold chain logistics on Oct 6 for $25.5M cash, streamlining to pure-play cell processing.
- Cash and marketable securities $98.4M as of Sep 30; no evo proceeds included.

## SEC filing metadata
- accession: 0001628280-25-050163
- form_type: 8-K
- ticker: BLFS
- cik: 0000834365
- company_name: BIOLIFE SOLUTIONS INC
- filed_at: 2025-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/834365/000162828025050163/0001628280-25-050163-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/834365/000162828025050163/blfs-20251106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-050163
- JSON: https://secwatch.observer/filing/0001628280-25-050163.json
- Plain text: https://secwatch.observer/filing/0001628280-25-050163.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.